We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vicarious Surgical (RBOT) to Broaden User Network With New Deal
Read MoreHide Full Article
Vicarious Surgical Inc. (RBOT - Free Report) recently inked a transformative agreement with Intermountain Health, a leading U.S. healthcare system. This strategic collaboration holds the potential to broaden Vicarious Surgical's surgical robotics business customer base while simultaneously improving patient outcomes and healthcare efficiencies.
Financial terms of the deal were not disclosed.
A Few Words on Intermountain Health
Headquartered in UT, Intermountain Health has a prominent presence in the U.S. healthcare sector as a nonprofit system. It comprises 33 hospitals, 385 clinics and a huge network of healthcare professionals. Its health plan division — Select Health — has more than one million members and other health services. Intermountain Health’s efforts to enhance community health and deliver advanced healthcare at sustainable costs have made it a leading player in transforming healthcare.
Image Source: Zacks Investment Research
Importance of the Deal
Vicarious Surgical's partnership with Intermountain Health will help the company gain access to Intermountain Health's extensive network. According to Vicarious Surgical, it will collaborate closely with Intermountain Health’s team of experienced robotic surgeons and integrated, managed-care business. This synergy aims to combine Intermountain Health’s expertise in delivering advanced clinical outcomes and system efficiencies while utilizing the Vicarious Surgical system.
With this partnership, patients will be offered a broad range of minimally invasive treatment options while surgeons will be given enhanced tools for cutting-edge surgical care.
According to Vicarious Surgical, this partnership also signifies a crucial step toward system finalization and regulatory submission.
Market Prospect
Per a recent Market.US report, the global surgical robotics market has a projected CAGR of 15.7%. Starting at $6.2 billion in 2022, it is forecast to surge to $25.7 billion by 2032. The surge in demand is driven by the advantages of robotic surgery, which offers doctors enhanced flexibility, precision and control in performing complex procedures through minimally invasive techniques. Economic factors, including the growing preference for automation and the adoption of advanced technologies, are expected to further fuel the market's expansion.
Share Price Performance
Shares of RBOT have plunged 80.1% over the past year compared with the industry’s 3.1% dip.
Zacks Rank and Key Picks
Vicarious Surgical currently carries a Zacks Rank #4 (Sell).
Haemonetics’ stock has risen 15% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 for 2023 and from $3.96 to $4.07 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 159.4% in the past year against the industry’s decline of 4.1%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 23.1% in the past year against the industry’s fall of 2.1%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Vicarious Surgical (RBOT) to Broaden User Network With New Deal
Vicarious Surgical Inc. (RBOT - Free Report) recently inked a transformative agreement with Intermountain Health, a leading U.S. healthcare system. This strategic collaboration holds the potential to broaden Vicarious Surgical's surgical robotics business customer base while simultaneously improving patient outcomes and healthcare efficiencies.
Financial terms of the deal were not disclosed.
A Few Words on Intermountain Health
Headquartered in UT, Intermountain Health has a prominent presence in the U.S. healthcare sector as a nonprofit system. It comprises 33 hospitals, 385 clinics and a huge network of healthcare professionals. Its health plan division — Select Health — has more than one million members and other health services. Intermountain Health’s efforts to enhance community health and deliver advanced healthcare at sustainable costs have made it a leading player in transforming healthcare.
Image Source: Zacks Investment Research
Importance of the Deal
Vicarious Surgical's partnership with Intermountain Health will help the company gain access to Intermountain Health's extensive network. According to Vicarious Surgical, it will collaborate closely with Intermountain Health’s team of experienced robotic surgeons and integrated, managed-care business. This synergy aims to combine Intermountain Health’s expertise in delivering advanced clinical outcomes and system efficiencies while utilizing the Vicarious Surgical system.
With this partnership, patients will be offered a broad range of minimally invasive treatment options while surgeons will be given enhanced tools for cutting-edge surgical care.
According to Vicarious Surgical, this partnership also signifies a crucial step toward system finalization and regulatory submission.
Market Prospect
Per a recent Market.US report, the global surgical robotics market has a projected CAGR of 15.7%. Starting at $6.2 billion in 2022, it is forecast to surge to $25.7 billion by 2032. The surge in demand is driven by the advantages of robotic surgery, which offers doctors enhanced flexibility, precision and control in performing complex procedures through minimally invasive techniques. Economic factors, including the growing preference for automation and the adoption of advanced technologies, are expected to further fuel the market's expansion.
Share Price Performance
Shares of RBOT have plunged 80.1% over the past year compared with the industry’s 3.1% dip.
Zacks Rank and Key Picks
Vicarious Surgical currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’ stock has risen 15% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 for 2023 and from $3.96 to $4.07 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 159.4% in the past year against the industry’s decline of 4.1%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 23.1% in the past year against the industry’s fall of 2.1%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.